Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of gemcitabine, carboplatin and veliparib in refractory testicular germ cell cancer
2016-000171-24Phase 2Completed
- Sponsor
- Národný onkologický ústav
- Start
- Apr 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of veliparib in germ cell tumor (GCT), Germ Cell Testicular Cancer, seminoma and 1 more, sponsored by Národný onkologický ústav. Primary endpoint: 12-month progression-free survival rate. Started Apr 2016; status: completed.
02
Drugs
veliparib
03
Conditions
germ cell tumor (GCT)Germ Cell Testicular Cancerseminomanon-seminomatous germ cell tumor (NSGCT)
Beyond the preview
Go deeper on 2016-000171-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000171-24.